CD133+ cells, in contrast with their CD133−counterparts, have shown an ability to self-renew, undergo multi-lineage differentiation (to neurons, astrocytes, and oligodendrocytes in vitro) and recapitulate the original tumor phenotype in vivo. This evidence concerns the gene PROM1 and neoplasm.